Aldoss I et al. Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in patients with relapsed or refractory (R/R) KMT2Ar acute leukemia. EHA 2025;Abstract PS1473.
Arellano ML et al. Patients with relapsed or refractory (R/R) nucleophosmin 1-mutated (NPM1m) acute myeloid leukemia (AML): Updated results from the phase 2 AUGMENT-101 study. EHA 2025;Abstract PS1467.
De Botton S et al. Effect of mutation type and co-mutations on response to olutasidenib in patients with relapsed/refractory mutated IDH1 AML. EHA 2025;Abstract PF516.
Erba H et al. Ziftomenib combined with intensive induction chemotherapy (7+3) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia (AML): Updated phase 1a/b results from KOMET-007. EHA 2025;Abstract S136.
Fathi AT et al. Ziftomenib combined with venetoclax/azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Interim phase 1a results from KOMET‑007. ASH 2024;Abstract 2880.
Levis M et al. The combination of a FLT3-ITD, NPM1MUT and an epigenetic regulatory gene mutation confers unique sensitivity to quizartinib: Analysis from the QUANTUM-FIRST trial. EHA 2025;Abstract S140.
Marvin-Peek J et al. A phase IB/2 trial of an all-oral “triplet” regimen for IDH-mutated myeloid malignancies: Decitabine/cedazuridine and venetoclax in combination with ivosidenib/enasidenib. EHA 2025;Abstract PS1471.
Montesinos P et al. QuANTUM-Wild: A phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in FLT3-ITD–negative acute myeloid leukemia (AML). ASCO 2025;Abstract TPS6580.
Wang ES et al. A phase 2 study of olutasidenib in relapsed/refractory acute myeloid leukemia: Outcomes by number of prior treatment regimens. ASCO 2025;Abstract 6545.
Wang ES et al. Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study. ASCO 2025;Abstract 6506.
Wang ES et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): A multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol 2024;25(10):1310-24. Abstract
Wei AH et al. RP2D determination of bleximenib in combination with VEN+AZA: Phase 1b study in ND & R/R AML with KMT2A/NPM1 alterations. EHA 2025;Abstract S137.
Yilmaz M et al. Phase I/II study of decitabine, venetoclax, and quizartinib triplet combination in FLT3-ITD mutated AML. EHA 2025;Abstract S142.
Zeidan AM et al. An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts. ASCO 2025;Abstract 6504.
Zeidan AM et al. Registrational phase 3 study of ziftomenib in combination with non-intensive or intensive chemotherapy for newly diagnosed NPM1-m AND/OR KMT2A-r acute myeloid leukemia (AML): The KOMET-017 trial. EHA 2025;Abstract PB2573.
Zeidner J et al. Azacitidine, venetoclax, and revumenib for newly diagnosed older adults with acute myeloid leukemia (AML) and NPM1 mutation or KMT2A rearrangement: Updated results from the Beat AML consortium. EHA 2025;Abstract S138.